Overall Perfomance for "Ultimate Stock Alerts"
The following three charts can be used by potential investors to gauge the performance of "Ultimate Stock Alerts":
1 out of 6 campaigns closed down on first day
2 out of 6 campaigns closed up on first day
3 out of 6 campaigns had no net effect
CTXR Promotional Newsletter
The following is a newsletter released by "Ultimate Stock Alerts" promoting Citius Pharmaceuticals Inc.
Don't Want Anymore Emails
This is an update of our newest alert, CTXR.
Following our alert on Friday, CTXR opened at 1.01 and rallied to a high of 1.15, experiencing upside of 13% before closing the day at 1.04.
As a reminder, last week the company announced several potentially significant developments.
On Tuesday, the company announced
Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones
In this press release, the company highlighted its 2022 Achieved and Anticipated Catalysts
Report Topline results of IONTAK Phase 3 trial April 2022
Initiate Halo-Lido Phase 2b trial April 2022
Submit IONTAK BLA application 2H 2022
Complete enrollment in Mino-Lok Phase 3 trial end of 2022
Complete enrollment in Halo-Lido Phase 2b trial end of 2022
As the company further explained
In April, we initiated our Phase 2b Halo-Lido trial for the treatment of hemorrhoids. By the end of 2022, we expect to complete trial enrollment. A data readout will follow upon validation and analysis of the information provided in the electronic patient reported outcome tool ePRO designed with guidance from the FDA. The results will be used to design the Phase 3 trial. As this product would ultimately be marketed directly to consumers, rather than to targeted physician and hospital groups like our other pipeline candidates, we will evaluate alternatives to optimize the value of this asset as we advance the program. Citius considers all strategic alternatives to maximize the value of our portfolio, individually and collectively, on an ongoing basis. We believe we remain well capitalized to advance our programs through multiple catalysts this year, and we plan to continue building long-term value in the business by focusing on execution, concluded Mr. Mazur.
In addition, on Friday, the company announced
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
As the company stated in this press release
The Mino-Lok Phase 3 pivotal superiority trial NCT02901717 is a multi-center, randomized, open-label, blinded study to determine the efficacy and safety of Mino-Lok MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium.
The primary endpoint for this study is the time in days following randomization to a catheter failure event between randomization and test of cure TOC Week 6 in the Intent-to-Treat ITT Population. Additional secondary endpoints will be assessed including microbiological eradication and clinical cure.
Subjects in the Mino-Lok arm receive one MLT dose daily with a dwell time of two to four hours for a total of seven doses. For subjects in the Control arm, the investigator determines the antibiotic used in the lock, dose, dwell time, and number of days of administration based on institutional standards or Infectious Diseases Society of America IDSA guidelines.
As the company further accomplishes its plans, it could position itself for increased opportunity.
Sources , , , , , , , , , , ,
Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
You should read and understand this disclaimer in its entirety before joining the website or emailblog list of UltimateStockAlerts.com the Publisher. The information collectively the Advertisement disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, andor losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission the SEC at www.sec.gov the Financial Industry Regulatory Authority the FINRA at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.govconsumercyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial andor legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 4622 for the distribution of this advertisement about CTXR dated 5922. Previously, owners and operators of the Publisher have been compensated twenty four thousand dollars by bank wire transfer on 122121 for the distribution of a prior advertisement about CTXR. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 21122 for the distribution of a prior advertisement about CTXR. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 111921 for the distribution of a prior advertisement about CTXR. Previously, owners and operators of the Publisher have been compensated twenty two thousand five hundred dollars by bank wire transfer on 83021 for the distribution of a prior advertisement about CTXR. Previously, owners and operators of the Publisher have been compensated twelve thousand five hundred dollars by bank wire transfer on 7621 for the distribution of a prior advertisement about CTXR. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about CTXR. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
www.UltimateStockAlerts.comDisclaimer and www.UltimateStockAlerts.comPrivacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of 1 a client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.
Our records indicate that . requested and confirmed to be added to UltimateStockAlerts.com on January 26, 2015.
6020 Bent Pine Dr, Orlando, FL 32822, USA